Post-Interleukin 1

Version vom 8. Juli 2020, 09:24 Uhr

32313848 ä. Precision medicine in COVID-19: IL-1 beta a potential target
32376597 2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
32228825 2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1
32373790 2020. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome
32482538 ä. Propuesta de uso de anakinra en el distres respiratorio agudo secundario a COVID-19
32456767 2020. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?
32438450 2020. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
32437739 2020. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.
32462848 2020. Interleukine-1 et blocage du COVID-19.
32422376 2020. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.
32437934 2020. Use of anakinra in severe COVID-19: a case report.
32501454 2020. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
32487869 2020. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?
32583087 2020. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.
32568376 2020. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.

32571730 2020. Anakinra, una alternativa potencial en el tratamiento de la infeccion respiratoria grave por SARS-CoV-2 refractaria a tocilizumab.